ADAG

Adagene Inc. develops antibody-based therapeutics using its Dynamic Precision Library platform, which includes three proprietary technologies: NEObody™, SAFEbody®, and POWERbody™. NEObody™ generates antibodies with dynamic binding sites that adapt to unique epitopes, while SAFEbody® creates masked antibodies that activate selectively in the tumor microenvironment to reduce off-target toxicity. POWERbody™ extends SAFEbody technology to bispecific T-cell engagers and antibody-drug conjugates. The company collaborates with global partners to create diverse product franchises for single-agent and combination therapies.